Roche (RHHBY) is being investigated by Romanian authorities for allegedly pursuing anticompetitive practices, the latest instance in which a large drug maker is probed by a European government for such behavior.
The company is suspected of having sold cancer medicines to its distributors at higher wholesale prices than the prices offered by its own subsidiary when bidding for hospital business. The other probe involves allegedly attempting to thwart a generic version of its Tarceva cancer drug from reaching the market.
About the Author Reprints
